Table 4.

Multivariate analyses of week 14 VTC values using the determined threshold, potential covariates, and week 30 FCP or week 30 CRP.

	CRP analysis group 2				FCP analysis group 2
	Individuals with Crohn’s disease		Individuals with ulcerative colitis		Individuals with Crohn’s disease
Variables	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
Week 14 VTC Threshold FCP: >18.10 μg/ml (CD) CRP: >22.25 μg/ml (CD) >17.35 μg/ml (UC)	3.21 (1.26, 8.17)	0.010	6.95 (1.81, 26.77)	0.005	2.19 (0.66, 7.32)	0.202
Age (years)	0.99 (0.96, 1.02)	0.350	0.99 (0.96, 1.02)	0.635	1.00 (0.96, 1.04)	0.840
Sex (female vs male)	1.10 (0.46, 2.60)	0.843	0.88 (0.27, 2.84)	0.834	4.29 (1.29, 14.29)	0.018
Week 0 albumin (g/l)	1.00 (0.91, 1.09)	0.971	0.98 (0.88, 1.09)	0.710	1.26 (1.01, 1.57)	0.040
Disease duration (>2 years vs ≤2 years)	1.63 (0.58, 4.63)	0.361	0.72 (0.20, 2.57)	0.611	1.14 (0.32, 4.00)	0.840
Biologic treatment exposure (bio-naïve vs bio-exposed)	1.49 (0.60, 3.70)	0.401	1.13 (0.36, 3.57)	0.840	1.58 (0.47, 5.34)	0.462

CD, Crohn’s disease; CRP, C-reactive protein; FCP, faecal calprotectin; UC, ulcerative colitis; VTC, vedolizumab trough concentration.

Bold P values indicate statistical significance at P < 0.05.

Italicized variables are the reference for each analysis.